Dabigatran – Idarucizumab-facilitated intravenous thrombolysis – Hemorrhagic transformation

We read with interest the cases reported by Tsai et al. [1] on hemorrhagic transformation associated with idarucizumab-facilitated intravenous thrombolysis for acute ischemic cerebrovascular accident. Hemorrhagic transformation should be an expected serious consequence with idarucizumab-facilitated intravenous thrombolysis. We previously raised a serious concern that while idarucizumab is very effective in neutralizing intravascular dabigatran activity and correcting clotting times profile, there is a dissociation between laboratory and clinical hemostasis [2 –4].
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research